ERLOTIREL 150MG TAB 30'S

About

ERLOTIREL 150MG TAB is a small molecule tyrosine kinase inhibitor that specifically targets the epidermal growth factor receptor (EGFR). EGFR is a protein found on the surface of many cancer cells, and its activation can lead to uncontrolled cell growth and division. By inhibiting EGFR, ERLOTIREL blocks the signaling pathways that promote tumor proliferation, survival, and metastasis. It is primarily indicated for the treatment of non-small cell lung cancer (NSCLC) with activating EGFR mutations, where it has shown significant efficacy in improving patient outcomes. It is also used in combination with gemcitabine for pancreatic cancer. This targeted therapy offers a personalized approach to cancer treatment, especially for patients with specific genetic markers.

Uses

• Treatment of non-small cell lung cancer (NSCLC) with EGFR mutations
• Management of pancreatic cancer in combination with gemcitabine
• Maintenance therapy for advanced NSCLC
• Other solid tumors (off-label)

Directions For Use

Take orally once daily, at least one hour before or two hours after a meal. Swallow tablets whole.

Benefits

• Effective in EGFR-mutated NSCLC
• Improves progression-free survival
• Oral administration for patient convenience
• Targeted therapy with specific mechanism of action
• Can be used as first-line or maintenance therapy
• Manageable side effect profile with supportive care

Side Effects

• Rash (acneiform)
• Diarrhea
• Anorexia (loss of appetite)
• Fatigue
• Nausea and vomiting
• Stomatitis (mouth sores)
• Dry skin
• Interstitial lung disease (ILD)
• Liver dysfunction
• Ocular disorders
• Hemorrhage
• Nail disorders

Safety Measures

• Alcohol - Avoid or limit alcohol due to potential for increased gastrointestinal irritation and liver toxicity.
• Pregnancy - Contraindicated; highly teratogenic. Use effective contraception during and after treatment.
• Breastfeeding - Contraindicated; drug may pass into breast milk and harm the infant.
• Liver - Use with caution; dose adjustment may be required in hepatic impairment; monitor liver function closely.
• Kidney - No specific dose adjustment required for mild-moderate impairment; use with caution in severe renal impairment.
• Lung - Monitor for interstitial lung disease (ILD); discontinue if new or worsening pulmonary symptoms develop.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.